

KADCYLA
(ado- trastuzumab emtansine)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have **ONE** of the following:

1. HER2-positive metastatic breast cancer
 - a. Received prior therapy with trastuzumab or trastuzumab with a taxane **OR**
 - b. Developed disease recurrence during or within six months of completing adjuvant therapy
2. HER2-positive early breast cancer
 - a. Patient has residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment

AND ALL of the following:

- a. Hepatic function and platelet counts monitored prior to initiation and prior to receiving each dose
- b. Left ventricular ejection fraction (LVEF) monitored prior to initiation and every three months or more frequently as clinically indicated during treatment
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 7 months after the last dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 4 months after the last dose
- e. Prescriber agrees to monitor for pulmonary toxicity

Prior - Approval Limits

Duration 12 months



Federal Employee Program.

KADCYLA

(ado- trastuzumab emtansine)

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. HER2-positive breast cancer

AND ALL of the following:

- a. Patient has not been diagnosed with nodular regenerative hyperplasia (NRH)
- b. Hepatic function and platelet count monitored prior to each dose
- c. Left ventricular ejection fraction (LVEF) monitored every three months or more frequently as clinically indicated during treatment
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 7 months after the last dose
- e. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 4 months after the last dose
- f. Prescriber agrees to monitor for pulmonary toxicity

Prior - Approval *Renewal* Limits

Same as above